nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—CDC42BPB—uterine cervix—vaginal cancer	0.0114	0.013	CbGeAlD
Nilotinib—CDC42BPB—urethra—vaginal cancer	0.0105	0.0119	CbGeAlD
Nilotinib—MAPK8—epithelium—vaginal cancer	0.0104	0.0118	CbGeAlD
Nilotinib—MAPK8—uterine cervix—vaginal cancer	0.0103	0.0117	CbGeAlD
Nilotinib—FRK—female reproductive system—vaginal cancer	0.0101	0.0115	CbGeAlD
Nilotinib—CDC42BPB—uterus—vaginal cancer	0.0095	0.0108	CbGeAlD
Nilotinib—MAPK8—urethra—vaginal cancer	0.00948	0.0108	CbGeAlD
Nilotinib—TIE1—epithelium—vaginal cancer	0.00902	0.0103	CbGeAlD
Nilotinib—TIE1—uterine cervix—vaginal cancer	0.00894	0.0102	CbGeAlD
Nilotinib—MAPK11—female reproductive system—vaginal cancer	0.00861	0.00981	CbGeAlD
Nilotinib—MAPK8—uterus—vaginal cancer	0.00859	0.00979	CbGeAlD
Nilotinib—CDC42BPB—female reproductive system—vaginal cancer	0.00854	0.00973	CbGeAlD
Nilotinib—EPHB3—uterine cervix—vaginal cancer	0.0085	0.00969	CbGeAlD
Nilotinib—TIE1—urethra—vaginal cancer	0.00822	0.00936	CbGeAlD
Nilotinib—MAP4K1—mammalian vulva—vaginal cancer	0.0082	0.00934	CbGeAlD
Nilotinib—MAPK11—female gonad—vaginal cancer	0.00784	0.00893	CbGeAlD
Nilotinib—EPHB3—urethra—vaginal cancer	0.00782	0.0089	CbGeAlD
Nilotinib—HCK—uterine cervix—vaginal cancer	0.00782	0.0089	CbGeAlD
Nilotinib—CDC42BPB—female gonad—vaginal cancer	0.00777	0.00885	CbGeAlD
Nilotinib—BRAF—endometrium—vaginal cancer	0.00775	0.00883	CbGeAlD
Nilotinib—CDC42BPB—vagina—vaginal cancer	0.00773	0.0088	CbGeAlD
Nilotinib—MAPK8—female reproductive system—vaginal cancer	0.00773	0.0088	CbGeAlD
Nilotinib—EPHA6—female reproductive system—vaginal cancer	0.00773	0.0088	CbGeAlD
Nilotinib—EPHB3—endometrium—vaginal cancer	0.00769	0.00876	CbGeAlD
Nilotinib—TIE1—uterus—vaginal cancer	0.00745	0.00849	CbGeAlD
Nilotinib—EPHB3—mammalian vulva—vaginal cancer	0.00744	0.00847	CbGeAlD
Nilotinib—HCK—urethra—vaginal cancer	0.00718	0.00818	CbGeAlD
Nilotinib—BRAF—uterus—vaginal cancer	0.00714	0.00814	CbGeAlD
Nilotinib—EPHB3—uterus—vaginal cancer	0.00709	0.00807	CbGeAlD
Nilotinib—HCK—endometrium—vaginal cancer	0.00707	0.00805	CbGeAlD
Nilotinib—MAPK8—female gonad—vaginal cancer	0.00703	0.00801	CbGeAlD
Nilotinib—CA3—uterine cervix—vaginal cancer	0.00702	0.00799	CbGeAlD
Nilotinib—MAPK8—vagina—vaginal cancer	0.00699	0.00796	CbGeAlD
Nilotinib—HCK—mammalian vulva—vaginal cancer	0.00684	0.00779	CbGeAlD
Nilotinib—TIE1—female reproductive system—vaginal cancer	0.0067	0.00763	CbGeAlD
Nilotinib—MAPK14—epithelium—vaginal cancer	0.00661	0.00752	CbGeAlD
Nilotinib—MAPK14—uterine cervix—vaginal cancer	0.00655	0.00746	CbGeAlD
Nilotinib—EPHA4—urethra—vaginal cancer	0.00653	0.00743	CbGeAlD
Nilotinib—LCK—uterine cervix—vaginal cancer	0.00652	0.00743	CbGeAlD
Nilotinib—HCK—uterus—vaginal cancer	0.00651	0.00742	CbGeAlD
Nilotinib—EPHB3—female reproductive system—vaginal cancer	0.00637	0.00726	CbGeAlD
Nilotinib—MAP4K1—vagina—vaginal cancer	0.00635	0.00723	CbGeAlD
Nilotinib—EPHB4—epithelium—vaginal cancer	0.00626	0.00713	CbGeAlD
Nilotinib—EPHA4—mammalian vulva—vaginal cancer	0.00621	0.00708	CbGeAlD
Nilotinib—EPHB4—uterine cervix—vaginal cancer	0.00621	0.00707	CbGeAlD
Nilotinib—EPHA2—epithelium—vaginal cancer	0.00614	0.007	CbGeAlD
Nilotinib—TIE1—female gonad—vaginal cancer	0.0061	0.00694	CbGeAlD
Nilotinib—EPHA2—uterine cervix—vaginal cancer	0.00609	0.00694	CbGeAlD
Nilotinib—FGR—urethra—vaginal cancer	0.00599	0.00683	CbGeAlD
Nilotinib—LCK—urethra—vaginal cancer	0.00599	0.00683	CbGeAlD
Nilotinib—TEK—epithelium—vaginal cancer	0.00599	0.00683	CbGeAlD
Nilotinib—EPHA4—uterus—vaginal cancer	0.00592	0.00674	CbGeAlD
Nilotinib—FGR—endometrium—vaginal cancer	0.0059	0.00672	CbGeAlD
Nilotinib—CA3—uterus—vaginal cancer	0.00585	0.00666	CbGeAlD
Nilotinib—BRAF—female gonad—vaginal cancer	0.00584	0.00666	CbGeAlD
Nilotinib—BRAF—vagina—vaginal cancer	0.00581	0.00662	CbGeAlD
Nilotinib—EPHB3—female gonad—vaginal cancer	0.0058	0.0066	CbGeAlD
Nilotinib—EPHB3—vagina—vaginal cancer	0.00576	0.00656	CbGeAlD
Nilotinib—FGR—mammalian vulva—vaginal cancer	0.00571	0.0065	CbGeAlD
Nilotinib—LCK—mammalian vulva—vaginal cancer	0.00571	0.0065	CbGeAlD
Nilotinib—EPHB4—urethra—vaginal cancer	0.00571	0.0065	CbGeAlD
Nilotinib—EPHB6—uterine cervix—vaginal cancer	0.00568	0.00647	CbGeAlD
Nilotinib—EPHB4—endometrium—vaginal cancer	0.00562	0.0064	CbGeAlD
Nilotinib—EPHA2—urethra—vaginal cancer	0.0056	0.00637	CbGeAlD
Nilotinib—EPHA2—endometrium—vaginal cancer	0.00551	0.00627	CbGeAlD
Nilotinib—TEK—urethra—vaginal cancer	0.00546	0.00622	CbGeAlD
Nilotinib—MAPK14—uterus—vaginal cancer	0.00546	0.00622	CbGeAlD
Nilotinib—LCK—uterus—vaginal cancer	0.00544	0.00619	CbGeAlD
Nilotinib—EPHB4—mammalian vulva—vaginal cancer	0.00543	0.00619	CbGeAlD
Nilotinib—TEK—endometrium—vaginal cancer	0.00537	0.00612	CbGeAlD
Nilotinib—EPHA2—mammalian vulva—vaginal cancer	0.00533	0.00607	CbGeAlD
Nilotinib—HCK—female gonad—vaginal cancer	0.00533	0.00607	CbGeAlD
Nilotinib—EPHA4—female reproductive system—vaginal cancer	0.00532	0.00606	CbGeAlD
Nilotinib—HCK—vagina—vaginal cancer	0.0053	0.00603	CbGeAlD
Nilotinib—ABL2—female gonad—vaginal cancer	0.00529	0.00603	CbGeAlD
Nilotinib—ABL2—vagina—vaginal cancer	0.00526	0.00599	CbGeAlD
Nilotinib—EPHB6—urethra—vaginal cancer	0.00522	0.00594	CbGeAlD
Nilotinib—EPHB4—uterus—vaginal cancer	0.00517	0.00589	CbGeAlD
Nilotinib—EPHB6—endometrium—vaginal cancer	0.00514	0.00585	CbGeAlD
Nilotinib—CA9—female reproductive system—vaginal cancer	0.00503	0.00573	CbGeAlD
Nilotinib—EPHB6—mammalian vulva—vaginal cancer	0.00497	0.00566	CbGeAlD
Nilotinib—TEK—uterus—vaginal cancer	0.00495	0.00564	CbGeAlD
Nilotinib—MAPK14—female reproductive system—vaginal cancer	0.00491	0.00559	CbGeAlD
Nilotinib—FGR—female reproductive system—vaginal cancer	0.00489	0.00557	CbGeAlD
Nilotinib—MAP2K5—uterine cervix—vaginal cancer	0.00486	0.00553	CbGeAlD
Nilotinib—EPHA4—female gonad—vaginal cancer	0.00484	0.00552	CbGeAlD
Nilotinib—EPHA4—vagina—vaginal cancer	0.00481	0.00548	CbGeAlD
Nilotinib—CA3—vagina—vaginal cancer	0.00475	0.00541	CbGeAlD
Nilotinib—CSF1R—uterine cervix—vaginal cancer	0.00474	0.0054	CbGeAlD
Nilotinib—EPHB4—female reproductive system—vaginal cancer	0.00465	0.0053	CbGeAlD
Nilotinib—EPHA2—female reproductive system—vaginal cancer	0.00456	0.0052	CbGeAlD
Nilotinib—PDGFRA—uterus—vaginal cancer	0.00449	0.00511	CbGeAlD
Nilotinib—MAPK14—female gonad—vaginal cancer	0.00447	0.00509	CbGeAlD
Nilotinib—MAP2K5—urethra—vaginal cancer	0.00446	0.00508	CbGeAlD
Nilotinib—TEK—female reproductive system—vaginal cancer	0.00445	0.00507	CbGeAlD
Nilotinib—FGR—female gonad—vaginal cancer	0.00445	0.00506	CbGeAlD
Nilotinib—LCK—female gonad—vaginal cancer	0.00445	0.00506	CbGeAlD
Nilotinib—MAPK14—vagina—vaginal cancer	0.00444	0.00505	CbGeAlD
Nilotinib—FGR—vagina—vaginal cancer	0.00442	0.00503	CbGeAlD
Nilotinib—LCK—vagina—vaginal cancer	0.00442	0.00503	CbGeAlD
Nilotinib—MAP2K5—endometrium—vaginal cancer	0.00439	0.005	CbGeAlD
Nilotinib—CSF1R—urethra—vaginal cancer	0.00436	0.00496	CbGeAlD
Nilotinib—KIT—epithelium—vaginal cancer	0.00434	0.00494	CbGeAlD
Nilotinib—KIT—uterine cervix—vaginal cancer	0.0043	0.0049	CbGeAlD
Nilotinib—CSF1R—endometrium—vaginal cancer	0.00429	0.00488	CbGeAlD
Nilotinib—MAP2K5—mammalian vulva—vaginal cancer	0.00425	0.00484	CbGeAlD
Nilotinib—PDGFRB—epithelium—vaginal cancer	0.00424	0.00483	CbGeAlD
Nilotinib—EPHB4—female gonad—vaginal cancer	0.00423	0.00482	CbGeAlD
Nilotinib—EPHB4—vagina—vaginal cancer	0.00421	0.00479	CbGeAlD
Nilotinib—PDGFRB—uterine cervix—vaginal cancer	0.0042	0.00479	CbGeAlD
Nilotinib—EPHA2—female gonad—vaginal cancer	0.00415	0.00473	CbGeAlD
Nilotinib—CSF1R—mammalian vulva—vaginal cancer	0.00415	0.00472	CbGeAlD
Nilotinib—EPHA2—vagina—vaginal cancer	0.00413	0.0047	CbGeAlD
Nilotinib—MAPK8—Downstream signaling in naïve CD8+ T cells—IFNA1—vaginal cancer	0.00406	0.0333	CbGpPWpGaD
Nilotinib—TEK—female gonad—vaginal cancer	0.00405	0.00461	CbGeAlD
Nilotinib—PDGFRA—female reproductive system—vaginal cancer	0.00403	0.00459	CbGeAlD
Nilotinib—KIT—urethra—vaginal cancer	0.00395	0.0045	CbGeAlD
Nilotinib—CSF1R—uterus—vaginal cancer	0.00395	0.0045	CbGeAlD
Nilotinib—KIT—endometrium—vaginal cancer	0.00389	0.00443	CbGeAlD
Nilotinib—EPHB6—female gonad—vaginal cancer	0.00387	0.00441	CbGeAlD
Nilotinib—PDGFRB—urethra—vaginal cancer	0.00386	0.0044	CbGeAlD
Nilotinib—EPHB6—vagina—vaginal cancer	0.00385	0.00438	CbGeAlD
Nilotinib—PDGFRB—endometrium—vaginal cancer	0.0038	0.00433	CbGeAlD
Nilotinib—HCK—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00378	0.031	CbGpPWpGaD
Nilotinib—KIT—mammalian vulva—vaginal cancer	0.00377	0.00429	CbGeAlD
Nilotinib—ABL1—uterine cervix—vaginal cancer	0.00375	0.00427	CbGeAlD
Nilotinib—CA12—female reproductive system—vaginal cancer	0.00372	0.00424	CbGeAlD
Nilotinib—PDGFRB—mammalian vulva—vaginal cancer	0.00368	0.00419	CbGeAlD
Nilotinib—PDGFRA—female gonad—vaginal cancer	0.00367	0.00418	CbGeAlD
Nilotinib—PDGFRA—vagina—vaginal cancer	0.00365	0.00415	CbGeAlD
Nilotinib—MAP2K5—female reproductive system—vaginal cancer	0.00364	0.00414	CbGeAlD
Nilotinib—KIT—uterus—vaginal cancer	0.00359	0.00409	CbGeAlD
Nilotinib—CSF1R—female reproductive system—vaginal cancer	0.00355	0.00404	CbGeAlD
Nilotinib—PDGFRB—uterus—vaginal cancer	0.0035	0.00399	CbGeAlD
Nilotinib—ABL1—urethra—vaginal cancer	0.00344	0.00392	CbGeAlD
Nilotinib—ABL1—endometrium—vaginal cancer	0.00339	0.00386	CbGeAlD
Nilotinib—MAPK11—Metabolism of mRNA—EIF4A3—vaginal cancer	0.00332	0.0272	CbGpPWpGaD
Nilotinib—MAP2K5—female gonad—vaginal cancer	0.00331	0.00377	CbGeAlD
Nilotinib—MAP2K5—vagina—vaginal cancer	0.00329	0.00375	CbGeAlD
Nilotinib—ABL1—mammalian vulva—vaginal cancer	0.00328	0.00373	CbGeAlD
Nilotinib—CSF1R—female gonad—vaginal cancer	0.00323	0.00368	CbGeAlD
Nilotinib—KIT—female reproductive system—vaginal cancer	0.00322	0.00367	CbGeAlD
Nilotinib—CSF1R—vagina—vaginal cancer	0.00321	0.00366	CbGeAlD
Nilotinib—BRAF—Downstream signaling in naïve CD8+ T cells—IFNA1—vaginal cancer	0.00321	0.0263	CbGpPWpGaD
Nilotinib—MAPK8—IL12 signaling mediated by STAT4—IL2—vaginal cancer	0.00316	0.0259	CbGpPWpGaD
Nilotinib—PDGFRB—female reproductive system—vaginal cancer	0.00315	0.00359	CbGeAlD
Nilotinib—ABL1—uterus—vaginal cancer	0.00312	0.00356	CbGeAlD
Nilotinib—CA1—female reproductive system—vaginal cancer	0.00295	0.00336	CbGeAlD
Nilotinib—KIT—female gonad—vaginal cancer	0.00293	0.00334	CbGeAlD
Nilotinib—KIT—vagina—vaginal cancer	0.00292	0.00332	CbGeAlD
Nilotinib—TEK—SHP2 signaling—IL2—vaginal cancer	0.00288	0.0236	CbGpPWpGaD
Nilotinib—MAPK8—Toll-like Receptor Signaling Pathway—IFNA1—vaginal cancer	0.00287	0.0235	CbGpPWpGaD
Nilotinib—PDGFRB—female gonad—vaginal cancer	0.00287	0.00326	CbGeAlD
Nilotinib—PDGFRB—vagina—vaginal cancer	0.00285	0.00324	CbGeAlD
Nilotinib—MAPK11—Metabolism of RNA—EIF4A3—vaginal cancer	0.00284	0.0233	CbGpPWpGaD
Nilotinib—CA4—urethra—vaginal cancer	0.00283	0.00322	CbGeAlD
Nilotinib—ABL1—female reproductive system—vaginal cancer	0.00281	0.0032	CbGeAlD
Nilotinib—CA2—epithelium—vaginal cancer	0.00257	0.00293	CbGeAlD
Nilotinib—HCK—Interleukin-3, 5 and GM-CSF signaling—IL2—vaginal cancer	0.00257	0.021	CbGpPWpGaD
Nilotinib—ABL1—female gonad—vaginal cancer	0.00255	0.00291	CbGeAlD
Nilotinib—ABL1—vagina—vaginal cancer	0.00254	0.00289	CbGeAlD
Nilotinib—MAPK14—Metabolism of mRNA—EIF4A3—vaginal cancer	0.00237	0.0194	CbGpPWpGaD
Nilotinib—ABCG2—uterine cervix—vaginal cancer	0.00236	0.00269	CbGeAlD
Nilotinib—CA4—female reproductive system—vaginal cancer	0.00231	0.00263	CbGeAlD
Nilotinib—MAPK11—Toll-like Receptor Signaling Pathway—IFNA1—vaginal cancer	0.00229	0.0187	CbGpPWpGaD
Nilotinib—MAPK8—Regulation of toll-like receptor signaling pathway—IFNA1—vaginal cancer	0.00224	0.0184	CbGpPWpGaD
Nilotinib—CA2—mammalian vulva—vaginal cancer	0.00223	0.00254	CbGeAlD
Nilotinib—CYP2C8—endometrium—vaginal cancer	0.0022	0.0025	CbGeAlD
Nilotinib—ABCG2—urethra—vaginal cancer	0.00217	0.00247	CbGeAlD
Nilotinib—ABCG2—endometrium—vaginal cancer	0.00214	0.00243	CbGeAlD
Nilotinib—CA4—female gonad—vaginal cancer	0.0021	0.00239	CbGeAlD
Nilotinib—ABCG2—mammalian vulva—vaginal cancer	0.00207	0.00235	CbGeAlD
Nilotinib—LYN—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00205	0.0168	CbGpPWpGaD
Nilotinib—MAPK14—Metabolism of RNA—EIF4A3—vaginal cancer	0.00203	0.0166	CbGpPWpGaD
Nilotinib—MAPK8—IL2-mediated signaling events—IL2—vaginal cancer	0.00197	0.0162	CbGpPWpGaD
Nilotinib—ABCG2—uterus—vaginal cancer	0.00197	0.00224	CbGeAlD
Nilotinib—CA2—female reproductive system—vaginal cancer	0.00191	0.00218	CbGeAlD
Nilotinib—CYP2C8—female reproductive system—vaginal cancer	0.00182	0.00207	CbGeAlD
Nilotinib—MAPK11—Regulation of toll-like receptor signaling pathway—IFNA1—vaginal cancer	0.00178	0.0146	CbGpPWpGaD
Nilotinib—CA2—female gonad—vaginal cancer	0.00174	0.00198	CbGeAlD
Nilotinib—CA2—vagina—vaginal cancer	0.00173	0.00197	CbGeAlD
Nilotinib—EPHA4—Spinal Cord Injury—IL2—vaginal cancer	0.0017	0.014	CbGpPWpGaD
Nilotinib—LCK—Cytokine Signaling in Immune system—EIF4A3—vaginal cancer	0.00168	0.0138	CbGpPWpGaD
Nilotinib—MAPK8—Downstream signaling in naïve CD8+ T cells—IL2—vaginal cancer	0.00168	0.0138	CbGpPWpGaD
Nilotinib—CYP2C8—vagina—vaginal cancer	0.00165	0.00188	CbGeAlD
Nilotinib—CYP2B6—female reproductive system—vaginal cancer	0.00163	0.00186	CbGeAlD
Nilotinib—MAPK14—Toll-like Receptor Signaling Pathway—IFNA1—vaginal cancer	0.00163	0.0134	CbGpPWpGaD
Nilotinib—CYP2C9—female reproductive system—vaginal cancer	0.00162	0.00184	CbGeAlD
Nilotinib—ABCG2—female gonad—vaginal cancer	0.00161	0.00183	CbGeAlD
Nilotinib—ABCG2—vagina—vaginal cancer	0.0016	0.00182	CbGeAlD
Nilotinib—LCK—T-Cell Receptor and Co-stimulatory Signaling—IL2—vaginal cancer	0.0016	0.0131	CbGpPWpGaD
Nilotinib—MAPK11—IL2-mediated signaling events—IL2—vaginal cancer	0.00157	0.0129	CbGpPWpGaD
Nilotinib—LCK—IL2 signaling events mediated by STAT5—IL2—vaginal cancer	0.00155	0.0127	CbGpPWpGaD
Nilotinib—LCK—Inflammatory Response Pathway—IL2—vaginal cancer	0.00155	0.0127	CbGpPWpGaD
Nilotinib—LYN—IL-5 Signaling Pathway—IL2—vaginal cancer	0.0015	0.0123	CbGpPWpGaD
Nilotinib—CYP2B6—vagina—vaginal cancer	0.00148	0.00168	CbGeAlD
Nilotinib—MAPK8—Glucocorticoid receptor regulatory network—IL2—vaginal cancer	0.00141	0.0116	CbGpPWpGaD
Nilotinib—HCK—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.00141	0.0116	CbGpPWpGaD
Nilotinib—LYN—Interleukin-3, 5 and GM-CSF signaling—IL2—vaginal cancer	0.00139	0.0114	CbGpPWpGaD
Nilotinib—ABL1—Factors involved in megakaryocyte development and platelet production—IFNA1—vaginal cancer	0.00136	0.0112	CbGpPWpGaD
Nilotinib—BRAF—Downstream signaling in naïve CD8+ T cells—IL2—vaginal cancer	0.00133	0.0109	CbGpPWpGaD
Nilotinib—LCK—IL2 signaling events mediated by PI3K—IL2—vaginal cancer	0.00131	0.0108	CbGpPWpGaD
Nilotinib—MAPK8—Corticotropin-releasing hormone—IL2—vaginal cancer	0.00129	0.0106	CbGpPWpGaD
Nilotinib—LYN—GPVI-mediated activation cascade—IL2—vaginal cancer	0.00128	0.0105	CbGpPWpGaD
Nilotinib—MAPK14—Regulation of toll-like receptor signaling pathway—IFNA1—vaginal cancer	0.00127	0.0104	CbGpPWpGaD
Nilotinib—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—vaginal cancer	0.00126	0.0103	CbGpPWpGaD
Nilotinib—HCK—Signaling by Interleukins—IL2—vaginal cancer	0.00125	0.0103	CbGpPWpGaD
Nilotinib—HCK—Immune System—EIF4A3—vaginal cancer	0.00123	0.0101	CbGpPWpGaD
Nilotinib—CYP3A4—female reproductive system—vaginal cancer	0.00123	0.0014	CbGeAlD
Nilotinib—TEK—Hemostasis—IFNA1—vaginal cancer	0.00123	0.0101	CbGpPWpGaD
Nilotinib—CYP2D6—female reproductive system—vaginal cancer	0.00121	0.00138	CbGeAlD
Nilotinib—LCK—IL-2 Signaling Pathway—IL2—vaginal cancer	0.00119	0.00973	CbGpPWpGaD
Nilotinib—ABCB1—epithelium—vaginal cancer	0.00117	0.00134	CbGeAlD
Nilotinib—ABCB1—uterine cervix—vaginal cancer	0.00116	0.00133	CbGeAlD
Nilotinib—PDGFRB—SHP2 signaling—IL2—vaginal cancer	0.00114	0.00936	CbGpPWpGaD
Nilotinib—MAPK11—Glucocorticoid receptor regulatory network—IL2—vaginal cancer	0.00113	0.00923	CbGpPWpGaD
Nilotinib—MAPK14—IL2-mediated signaling events—IL2—vaginal cancer	0.00112	0.0092	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—EIF4A3—vaginal cancer	0.00112	0.00916	CbGpPWpGaD
Nilotinib—BLK—Immune System—EIF4A3—vaginal cancer	0.00112	0.00916	CbGpPWpGaD
Nilotinib—FGR—Immune System—EIF4A3—vaginal cancer	0.00111	0.00913	CbGpPWpGaD
Nilotinib—CYP2D6—female gonad—vaginal cancer	0.0011	0.00126	CbGeAlD
Nilotinib—LCK—Interleukin-2 signaling—IL2—vaginal cancer	0.00108	0.00889	CbGpPWpGaD
Nilotinib—ABCB1—urethra—vaginal cancer	0.00107	0.00122	CbGeAlD
Nilotinib—ABCB1—endometrium—vaginal cancer	0.00105	0.0012	CbGeAlD
Nilotinib—LCK—GPVI-mediated activation cascade—IL2—vaginal cancer	0.00105	0.0086	CbGpPWpGaD
Nilotinib—MAPK14—IL12-mediated signaling events—IL2—vaginal cancer	0.00103	0.00846	CbGpPWpGaD
Nilotinib—ABCB1—mammalian vulva—vaginal cancer	0.00102	0.00116	CbGeAlD
Nilotinib—BRAF—Corticotropin-releasing hormone—IL2—vaginal cancer	0.00102	0.00834	CbGpPWpGaD
Nilotinib—PDGFRA—Allograft Rejection—IL2—vaginal cancer	0.00099	0.00812	CbGpPWpGaD
Nilotinib—ABL1—Regulation of Telomerase—IL2—vaginal cancer	0.00098	0.00803	CbGpPWpGaD
Nilotinib—ABCB1—uterus—vaginal cancer	0.000971	0.00111	CbGeAlD
Nilotinib—LCK—IL2-mediated signaling events—IL2—vaginal cancer	0.00097	0.00795	CbGpPWpGaD
Nilotinib—LCK—SHP2 signaling—IL2—vaginal cancer	0.000916	0.00751	CbGpPWpGaD
Nilotinib—LCK—IL12-mediated signaling events—IL2—vaginal cancer	0.000892	0.00731	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—EIF4A3—vaginal cancer	0.00089	0.0073	CbGpPWpGaD
Nilotinib—MAPK11—Gene Expression—EIF4A3—vaginal cancer	0.000885	0.00726	CbGpPWpGaD
Nilotinib—ABCB1—female reproductive system—vaginal cancer	0.000873	0.000994	CbGeAlD
Nilotinib—MAPK14—Glucocorticoid receptor regulatory network—IL2—vaginal cancer	0.000803	0.00659	CbGpPWpGaD
Nilotinib—KIT—Immune System—EIF4A3—vaginal cancer	0.000803	0.00658	CbGpPWpGaD
Nilotinib—ABCB1—female gonad—vaginal cancer	0.000794	0.000905	CbGeAlD
Nilotinib—FGR—Hemostasis—IFNA1—vaginal cancer	0.000794	0.00651	CbGpPWpGaD
Nilotinib—HCK—Innate Immune System—IFNA1—vaginal cancer	0.000792	0.00649	CbGpPWpGaD
Nilotinib—ABCB1—vagina—vaginal cancer	0.000789	0.000899	CbGeAlD
Nilotinib—LYN—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.000767	0.00629	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—EIF4A3—vaginal cancer	0.00076	0.00623	CbGpPWpGaD
Nilotinib—MAPK14—Corticotropin-releasing hormone—IL2—vaginal cancer	0.000733	0.00601	CbGpPWpGaD
Nilotinib—MAPK8—Innate Immune System—IFNA1—vaginal cancer	0.000717	0.00588	CbGpPWpGaD
Nilotinib—FGR—Innate Immune System—IFNA1—vaginal cancer	0.000715	0.00586	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—EIF4A3—vaginal cancer	0.000685	0.00561	CbGpPWpGaD
Nilotinib—LYN—Signaling by Interleukins—IL2—vaginal cancer	0.00068	0.00557	CbGpPWpGaD
Nilotinib—LYN—Immune System—EIF4A3—vaginal cancer	0.00067	0.0055	CbGpPWpGaD
Nilotinib—ABL1—Immune System—EIF4A3—vaginal cancer	0.000667	0.00547	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—EIF4A3—vaginal cancer	0.000635	0.00521	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—EIF4A3—vaginal cancer	0.000632	0.00518	CbGpPWpGaD
Nilotinib—LCK—Cytokine Signaling in Immune system—IFNA1—vaginal cancer	0.000629	0.00516	CbGpPWpGaD
Nilotinib—HCK—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000584	0.00479	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—IFNA1—vaginal cancer	0.000572	0.00469	CbGpPWpGaD
Nilotinib—LCK—Signaling by Interleukins—IL2—vaginal cancer	0.000557	0.00457	CbGpPWpGaD
Nilotinib—LCK—Immune System—EIF4A3—vaginal cancer	0.000549	0.0045	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—IFNA1—vaginal cancer	0.000515	0.00422	CbGpPWpGaD
Nilotinib—TEK—Hemostasis—IL2—vaginal cancer	0.00051	0.00418	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—IFNA1—vaginal cancer	0.000488	0.004	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—IFNA1—vaginal cancer	0.000478	0.00392	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—IFNA1—vaginal cancer	0.000476	0.0039	CbGpPWpGaD
Nilotinib—HCK—Immune System—IFNA1—vaginal cancer	0.000461	0.00378	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—IFNA1—vaginal cancer	0.000453	0.00371	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—IFNA1—vaginal cancer	0.000439	0.0036	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—IFNA1—vaginal cancer	0.00043	0.00353	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—IFNA1—vaginal cancer	0.000428	0.00351	CbGpPWpGaD
Nilotinib—BLK—Immune System—IFNA1—vaginal cancer	0.000418	0.00342	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—IFNA1—vaginal cancer	0.000418	0.00342	CbGpPWpGaD
Nilotinib—FGR—Immune System—IFNA1—vaginal cancer	0.000416	0.00341	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—IFNA1—vaginal cancer	0.000408	0.00334	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—IFNA1—vaginal cancer	0.000392	0.00321	CbGpPWpGaD
Nilotinib—LYN—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000383	0.00314	CbGpPWpGaD
Nilotinib—ABCB1—Allograft Rejection—IL2—vaginal cancer	0.000375	0.00307	CbGpPWpGaD
Nilotinib—MAPK14—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000363	0.00298	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—IFNA1—vaginal cancer	0.000353	0.00289	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IFNA1—vaginal cancer	0.000333	0.00273	CbGpPWpGaD
Nilotinib—FGR—Hemostasis—IL2—vaginal cancer	0.000328	0.00269	CbGpPWpGaD
Nilotinib—LYN—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.000317	0.0026	CbGpPWpGaD
Nilotinib—LCK—Platelet activation, signaling and aggregation—IL2—vaginal cancer	0.000314	0.00258	CbGpPWpGaD
Nilotinib—KIT—Immune System—IFNA1—vaginal cancer	0.0003	0.00246	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IFNA1—vaginal cancer	0.000284	0.00233	CbGpPWpGaD
Nilotinib—LCK—Cytokine Signaling in Immune system—IL2—vaginal cancer	0.00026	0.00213	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IFNA1—vaginal cancer	0.000256	0.0021	CbGpPWpGaD
Nilotinib—LYN—Immune System—IFNA1—vaginal cancer	0.000251	0.00205	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IFNA1—vaginal cancer	0.000249	0.00204	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IFNA1—vaginal cancer	0.000238	0.00195	CbGpPWpGaD
Nilotinib—LCK—Immune System—IFNA1—vaginal cancer	0.000205	0.00168	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—IL2—vaginal cancer	0.000198	0.00162	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—IL2—vaginal cancer	0.000197	0.00161	CbGpPWpGaD
Nilotinib—HCK—Immune System—IL2—vaginal cancer	0.000191	0.00156	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—IL2—vaginal cancer	0.000187	0.00154	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—IL2—vaginal cancer	0.000173	0.00142	CbGpPWpGaD
Nilotinib—BLK—Immune System—IL2—vaginal cancer	0.000173	0.00142	CbGpPWpGaD
Nilotinib—FGR—Immune System—IL2—vaginal cancer	0.000172	0.00141	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—IL2—vaginal cancer	0.000162	0.00133	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL2—vaginal cancer	0.000138	0.00113	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL2—vaginal cancer	0.000124	0.00102	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL2—vaginal cancer	0.000117	0.000963	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL2—vaginal cancer	0.000112	0.000916	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL2—vaginal cancer	0.000106	0.000871	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL2—vaginal cancer	0.000106	0.000868	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL2—vaginal cancer	0.000104	0.00085	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL2—vaginal cancer	0.000103	0.000846	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL2—vaginal cancer	9.82e-05	0.000805	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL2—vaginal cancer	8.9e-05	0.00073	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL2—vaginal cancer	8.82e-05	0.000723	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL2—vaginal cancer	8.49e-05	0.000696	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL2—vaginal cancer	8.02e-05	0.000658	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL2—vaginal cancer	7.6e-05	0.000623	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL2—vaginal cancer	6.84e-05	0.000561	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL2—vaginal cancer	6.7e-05	0.000549	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL2—vaginal cancer	6.35e-05	0.000521	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL2—vaginal cancer	5.49e-05	0.00045	CbGpPWpGaD
